Ruiz-Domínguez R, Cuentas-Yáñez G, Da Re-Gutiérrez S

Language: Spanish
References: 21
Page: 196-201
PDF size: 502.27 Kb.

ABSTRACT

The term catastrophic antiphospholipid syndrome (CAPS) defines an accelerated form of antiphospholipid syndrome resulting in multiorgan failure and death. In this presentation all patients develop small vessel occlusion in a short course of time (days to weeks), with a mortality of 50%. For its treatment, glucocorticoids, heparin, plasma exchange, cyclophosphamide and IVIG are used. This paper reports the case of a male patient who rapidly developed multiorganic failure, thrombosis and posterior aseptic necrosis of the right leg, and survived thanks to the early multidisciplinary treatment but with the loss of the compromised leg.

REFERENCES

1. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology 2005;210:727-733.

2. Asherson RA. The catastrophic antiphospholipid antibody syndrome. J Rheumatol 1992;19:508-512.

3. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-376.

4. Piette J, Cervera R, Levy RA, et al. The catastrophic antiphospholipid syndrome-Asherson’s syndrome. Paris: Ann Med Intern 2003;154:195-196.

5. Cervera R, CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the “CAPS Registry”. Lupus 2010;19:412-418.

6. Erkan D, Cervera R, Asherson RA. Catastrophic antihospholipid syndrome: Where do we stand? Arthritis Rheum 2003;48:3320-3327.

7. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012;38:333-338.

8. Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009;18:905-912.

9. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-1027.

10. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033- 1044.

11. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-534.

12. Myyakis S, Lockshin MD, Atsumi T, et al. International Consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.

13. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763.

14. Asherson RA, Cervera R. The catastrophic antiphospholipid antibody syndrome: a review of pathogenesis, clinical features and treatment. IMAJ 2000;2:268-273.

15. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: update diagnostic algorithms. Autoimmune Rev 2010;10:74-79.

16. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009;32:240-245.

17. Sangle NA, Path FR, Smock KJ. Antiphospholipid antibody syndrome. Arch Pathol Lab Med 2011;135:1092-1096.

18. Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC. Catastrophic antiphospholipid syndrome. Proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002;8:157-165.

19. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010;12:70-76.

20. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection mechanisms of action and treatment. J Intern Med 2011;270:110-122.

21. Ruiz DR, Huanca MI. Debut de lupus eritematoso sistémico con síndrome antifosfolipídico catastrófico: beneficio del tratamiento precoz. An Med Interna (Madrid) 2007;24:339- 341.